GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Shandong Boan Biotechnology Co Ltd (FRA:UJ9) » Definitions » EBIT

Shandong Boan Biotechnology Co (FRA:UJ9) EBIT : €10.50 Mil (TTM As of Jun. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Shandong Boan Biotechnology Co EBIT?

Shandong Boan Biotechnology Co's earnings before interest and taxes (EBIT) for the six months ended in Jun. 2024 was €9.51 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Jun. 2024 was €10.50 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Shandong Boan Biotechnology Co's annualized ROC % for the quarter that ended in Jun. 2024 was 3.86%. Shandong Boan Biotechnology Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2024 was 20.58%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Shandong Boan Biotechnology Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2024 was 1.63%.

Shandong Boan Biotechnology Co EBIT Historical Data

The historical data trend for Shandong Boan Biotechnology Co's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shandong Boan Biotechnology Co EBIT Chart

Shandong Boan Biotechnology Co Annual Data
Trend Dec20 Dec21 Dec22 Dec23
EBIT
-28.75 -29.71 -43.11 -13.52

Shandong Boan Biotechnology Co Semi-Annual Data
Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
EBIT Get a 7-Day Free Trial -20.72 -23.25 -14.57 0.99 9.51

Competitive Comparison of Shandong Boan Biotechnology Co's EBIT

For the Biotechnology subindustry, Shandong Boan Biotechnology Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Shandong Boan Biotechnology Co's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Shandong Boan Biotechnology Co's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Shandong Boan Biotechnology Co's EV-to-EBIT falls into.


Shandong Boan Biotechnology Co EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was €10.50 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Shandong Boan Biotechnology Co  (FRA:UJ9) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Shandong Boan Biotechnology Co's annualized ROC % for the quarter that ended in Jun. 2024 is calculated as:

ROC % (Q: Jun. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2023 ) + Invested Capital (Q: Jun. 2024 ))/ count )
=9.804 * ( 1 - 0% )/( (251.966 + 256.174)/ 2 )
=9.804/254.07
=3.86 %

where

Invested Capital(Q: Dec. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=298.387 - 38.759 - ( 25.923 - max(0, 83.908 - 91.57+25.923))
=251.966

Invested Capital(Q: Jun. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=326.333 - 48.118 - ( 22.041 - max(0, 71.151 - 95.916+22.041))
=256.174

Note: The Operating Income data used here is two times the semi-annual (Jun. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Shandong Boan Biotechnology Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2024 is calculated as:

ROC (Joel Greenblatt) %(Q: Jun. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2023  Q: Jun. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=19.02/( ( (84.746 + max(-4.488, 0)) + (84.505 + max(15.615, 0)) )/ 2 )
=19.02/( ( 84.746 + 100.12 )/ 2 )
=19.02/92.433
=20.58 %

where Working Capital is:

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(27.381 + 21.228 + 8.798) - (38.759 + 0 + 23.136)
=-4.488

Working Capital(Q: Jun. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(40.151 + 22.791 + 0.792) - (48.118 + 0 + 0.00099999999999056)
=15.615

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Jun. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Shandong Boan Biotechnology Co's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Jun. 2024 )
=10.503/644.875
=1.63 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Shandong Boan Biotechnology Co EBIT Related Terms

Thank you for viewing the detailed overview of Shandong Boan Biotechnology Co's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Shandong Boan Biotechnology Co Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Shandong Boan Biotechnology Co Ltd (FRA:UJ9) » Definitions » EBIT
Comparable Companies
HKSE:02315 HKSE:02105 HKSE:06855 HKSE:02696 HKSE:02480 HKSE:00775 HKSE:02157 HKSE:01952 HKSE:02171 HKSE:02487 OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
06955:Hong Kong
Address
No. 39 Keji Avenue, High-Tech Industrial Development Zone, Shandong Province, Yantai, CHN
Website
https://www.boan-bio.com
Shandong Boan Biotechnology Co Ltd is a fully integrated biopharmaceutical company. The company is engaged in the development, manufacture, and commercialization of high-quality biologics in China and around the world. It focuses on areas such as oncology, metabolism, autoimmunity, and ophthalmology. Geographically company's revenue is generated from customers located in Mainland China.

Shandong Boan Biotechnology Co Headlines

No Headlines